Treatment-free remission in patients with chronic myeloid leukaemia.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
accepted:
01
04
2020
pubmed:
8
5
2020
medline:
3
11
2020
entrez:
8
5
2020
Statut:
ppublish
Résumé
In the past few years, international treatment guidelines for chronic myeloid leukaemia have incorporated recommendations for attempting discontinuation of treatment with tyrosine-kinase inhibitors (TKIs) outside of the setting of a clinical trial with the aim of a treatment-free remission (TFR). Physicians involved in the treatment of chronic myeloid leukaemia need to be sufficiently well informed to guide patients through decision-making about the discontinuation of treatment with TKIs targeting BCR-ABL1 by providing a balanced assessment of the potential risks and benefits of stopping or continuing therapy. These guidelines also seek to ensure that the risks associated with being off treatment are kept to a minimum. In this Review, we summarize the clinical studies of TFR and how their results can guide routine clinical practice with a focus on specific aspects such as molecular monitoring and the pregnancy-specific risks associated with a TFR attempt in female patients. We also address the development of predictors of outcome after TKI discontinuation and present strategies that warrant further consideration to enable more patients to enter TFR.
Identifiants
pubmed: 32377005
doi: 10.1038/s41571-020-0367-1
pii: 10.1038/s41571-020-0367-1
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-503Références
Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343–3356 (2000).
pubmed: 11071626
Branford, S. et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 33, 1835–1850 (2019).
pubmed: 31209280
pmcid: 6893870
Swerdlow, S. H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn (IARC, 2017).
Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
pubmed: 17151364
Saussele, S. et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126, 42–49 (2015).
pubmed: 25918346
pmcid: 4574015
Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30, 1044–1054 (2016).
pubmed: 26837842
pmcid: 4858585
Cortes, J. E. et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J. Clin. Oncol. 34, 2333–2340 (2016).
pubmed: 27217448
pmcid: 5118045
Lipton, J. H. et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 17, 612–621 (2016).
pubmed: 27083332
Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Eng. J. Med. 376, 917–927 (2017).
Goldman, J. & Gordon, M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk. Lymphoma 47, 1–7 (2006).
pubmed: 16321820
Guilhot, F. et al. French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med. 337, 223–229 (1997).
pubmed: 9227927
O’Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
pubmed: 12637609
Baccarani, M. et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33, 1173–1183 (2019).
pubmed: 30675008
Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28–37 (2006).
pubmed: 16522812
pmcid: 1895821
Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003).
pubmed: 14534335
Branford, S. et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin. Cancer Res. 13, 7080–7085 (2007).
pubmed: 18056186
Branford, S. et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20, 1925–1930 (2006).
pubmed: 16990771
Cross, N. C. et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29, 999–1003 (2015).
pubmed: 25652737
pmcid: 4430701
Hehlmann, R. et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J. Clin. Oncol. 32, 415–423 (2014).
pubmed: 24297946
Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58–60 (2007).
pubmed: 16973963
National Comprehensive Cancer Network. Chronic Myeloid Leukemia www.nccn.org (2017).
Hochhaus, A. et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28 (Suppl. 4), iv41–iv51 (2017).
Hughes, T. P. & Ross, D. M. Moving treatment-free remission into mainstream clinical practice in CML. Blood 128, 17–23 (2016).
pubmed: 27013442
Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029–1035 (2010).
pubmed: 20965785
Etienne, G. et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J. Clin. Oncol. 35, 298–305 (2017).
pubmed: 28095277
Ross, D. M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515–522 (2013).
pubmed: 23704092
Ross, D. M. et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia 32, 2572–2579 (2018).
pubmed: 30315232
Nicolini, F. E. et al. Evaluation of residual disease and tki duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin. Cancer Res. 25, 6606–6613 (2019).
pubmed: 31292142
Fujisawa, S. et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int. J. Clin. Oncol. 24, 445–453 (2019).
pubmed: 30421023
Rousselot, P. et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J. Clin. Oncol. 32, 424–430 (2014).
pubmed: 24323036
Lee, S. E. et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am. J. Hematol. 88, 449–454 (2013).
pubmed: 23440689
Mori, S. et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am. J. Hematol. 90, 910–914 (2015).
pubmed: 26178642
Takahashi, N. et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int. J. Hematol. 107, 185–193 (2018).
pubmed: 28929332
Saussele, S. et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 19, 747–757 (2018).
pubmed: 29735299
Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 4, e310–e316 (2017).
pubmed: 28566209
Clark, R. E. et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 6, e375–e383 (2019).
pubmed: 31201085
Branford, S. et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 119, 4264–4271 (2012).
pubmed: 22431575
Lee, S. E. et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101, 717–723 (2016).
pubmed: 26888022
pmcid: 5013960
Kimura, S. et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 7, e218–e225 (2020).
pubmed: 31978329
Imagawa, J. et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2, e528–e535 (2015).
pubmed: 26686407
Okada, M. et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin. Lymphoma Myeloma Leuk. 18, 353–360 (2018).
pubmed: 29610029
Kumagai, T. et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 109, 182–192 (2018).
pubmed: 29058817
Shah, N. P. et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk. Lymphoma 61, 650–659 (2020).
pubmed: 31647335
Rea, D. et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129, 846–854 (2017).
pubmed: 27932374
Takahashi, N. et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica 103, 1835–1842 (2018).
pubmed: 29976734
pmcid: 6278957
Mahon, F. X. et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann. Intern. Med. 168, 461–470 (2018).
pubmed: 29459949
Hochhaus, A. et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 31, 1525–1531 (2017).
pubmed: 28218239
pmcid: 5508077
Ross, D. M. et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J. Cancer Res. Clin. Oncol. 144, 945–954 (2018).
pubmed: 29468438
pmcid: 5916993
Baccarani, M. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108, 1809–1820 (2006).
pubmed: 16709930
Baccarani, M. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041–6051 (2009).
pubmed: 19884523
pmcid: 4979100
Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872–884 (2013).
pubmed: 23803709
pmcid: 4915804
Radich, J. P. et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 16, 1108–1135 (2018).
pubmed: 30181422
Shanmuganathan, N. et al. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood 134, 85–89 (2019).
pubmed: 30967368
Pagani, I. S. et al. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica 103, 2026–2032 (2018).
pubmed: 29976745
pmcid: 6269287
Falchi, L. et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am. J. Hematol. 88, 1024–1029 (2013).
pubmed: 23913852
Goldman, J. M. et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin. Oncol. 28, 1888–1895 (2010).
pubmed: 20212247
pmcid: 2860369
Sekhri, A. et al. Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk. Res. 33, 1291–1293 (2009).
pubmed: 19344950
Papalexandri, A. et al. Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop? HemaSphere 2, e157 (2018).
pubmed: 31723795
pmcid: 6745958
Rea, D. et al. Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): a FI-LMC STOP 2G-TKI study update. Blood 134, 30 (2019).
Benjamini, O. et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk. Lymphoma 55, 2879–2886 (2014).
pubmed: 23927391
Richter, J. et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J. Clin. Oncol. 32, 2821–2823 (2014).
pubmed: 25071107
Shah, N. P. et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk. Lymphoma 61, 650–659 (2020).
pubmed: 31647335
Berger, M. G. et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br. J. Haematol. 187, 337–346 (2019).
pubmed: 31271217
Katagiri, S. et al. Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey. Rinsho Ketsueki 57, 873–876 (2016).
pubmed: 27498732
Villemagne Sanchez, L. A. et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk. Lymphoma 59, 406–415 (2018).
pubmed: 28617066
Breccia, M. et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk. Res. 39, 1055–1059 (2015).
pubmed: 26282944
Jiang, Q., Liu, Z. C., Zhang, S. X. & Gale, R. P. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J. Cancer Res. Clin. Oncol. 142, 1539–1547 (2016).
pubmed: 27085529
Barnes, D. J. et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 65, 8912–8919 (2005).
pubmed: 16204063
Legros, L. et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer 123, 4403–4410 (2017).
pubmed: 28743166
Pye, S. M. et al. The effects of imatinib on pregnancy outcome. Blood 111, 5505–5508 (2008).
pubmed: 18322153
pmcid: 4916938
Cortes, J. E. et al. The impact of dasatinib on pregnancy outcomes. Am. J. Hematol. 90, 1111–1115 (2015).
pubmed: 26348106
pmcid: 5115878
Berman, E., Druker, B. J. & Burwick, R. Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy. J. Clin. Oncol. 36, 1250–1256 (2018).
pubmed: 29447062
Ross, D. M., Burbury, K. L., Grigg, A. P., Hughes, T. P. & Seymour, J. F. Management of pregnancy in women with chronic myeloid leukemia. J. Clin. Oncol. 36, 2657–2658 (2018).
pubmed: 29851544
Claudiani, S. et al. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica 102, e297–e299 (2017).
pubmed: 28495914
pmcid: 5541883
Sokal, J. E. et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63, 789–799 (1984).
pubmed: 6584184
Pfirrmann, M. et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30, 48–56 (2016).
pubmed: 26416462
D’Adda, M. et al. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer 125, 1674–1682 (2019).
pubmed: 30707758
Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24, 1719–1724 (2010).
pubmed: 20811403
Score, J. et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia 24, 1742–1750 (2010).
pubmed: 20703256
Ohyashiki, K. et al. Increased natural killer cells and decreased CD3
pubmed: 22077498
Ilander, M. et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31, 1108–1116 (2017).
pubmed: 27890936
Ross, D. M. et al. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. Br. J. Haematol. 186, e56–e60 (2019).
pubmed: 30916385
Schutz, C. et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia 32, 1054 (2018).
pubmed: 29381150
Pagani, I. S. et al. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica 103, 2026–2032 (2018).
pubmed: 29976745
pmcid: 6269287
Bocchia, M. et al. Residual peripheral blood CD26
pubmed: 29900128
pmcid: 5988870
Chomel, J. C. et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget 7, 35293–35301 (2016).
pubmed: 27167108
pmcid: 5085229
Houshmand, M. et al. Chronic myeloid leukemia stem cells. Leukemia 33, 1543–1556 (2019).
pubmed: 31127148
pmcid: 6755964
Ross, D. M., Hughes, T. P. & Melo, J. V. Do we have to kill the last CML cell? Leukemia 25, 193–200 (2011).
pubmed: 20844563
Cheah, C. Y. et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 123, 3574–3577 (2014).
pubmed: 24687085
pmcid: 4047496
Legrand, F. et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine 92, e1–e9 (2013).
pubmed: 23982058
pmcid: 4553979
Cerrano, M. et al. Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm. Am. J. Hematol. 91, E353 (2016).
pubmed: 27194679
Helbig, G., Soja, A., Swiderska, A., Hus, M. & Kyrcz-Krzemien, S. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Leuk. Lymphoma 57, 708–710 (2016).
pubmed: 26430910
Bidet, A. et al. Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation. Br. J. Haematol. 182, 148–152 (2018).
pubmed: 28485070
McMahon, C. M. et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 9, 1050–1063 (2019).
pubmed: 31088841
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
Jansen, Y. J. L. et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann. Oncol. 30, 1154–1161 (2019).
pubmed: 30923820
Tan, A. C. et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann. Oncol. 29, 2115–2120 (2018).
pubmed: 30137228
Seremet, T. et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J. Transl Med. 17, 303 (2019).
pubmed: 31488153
pmcid: 6727487
Dahlen, T. et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann. Intern. Med. 165, 161–166 (2016).
pubmed: 27295519
Yilmaz, M. et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121, 3894–3904 (2015).
pubmed: 26217876
pmcid: 4519988
Shih, Y. T., Cortes, J. E. & Kantarjian, H. M. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 6, e398–e408 (2019).
pubmed: 31208943
Loeliger, E. A., van den Besselaar, A. M. & Lewis, S. M. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb. Haemost. 53, 148–154 (1985).
pubmed: 3992514